A media company in India are ramping up criticism of COIVD-19 vaccine suppliers following the nation’s success at treating the virus with Ivermectin. In a recent report, Indian television channel WION claimed Pfizer is maximizing revenues by selling COVID-19 vaccines to developing nations on often predatory terms.
The findings, they say, reinforce policy decisions and recommendations around providing booster shots to vulnerable populations.
The White House on Tuesday told states to prepare to vaccinate children as young as 5 by early November, even though the U.S. Food and Drug Administration hasn’t yet authorized Pfizer’s COVID vaccine for children under 12, and despite safety concerns expressed by scientists and pediatricians.
Trigger alert: This article may upset those who care about other human beings.
Molnupiravir (mull-noo-’peer-aveer) is the talk of the town, belle of the ball in the press. “Game changer” is the word on the street, according to a message to Science Insider:
“Molnupiravir is unquestionably a game changer! The large effect size, and the ease of administration change the paradigm of mild COVID-19 treatment with a potential to reduce COVID-19 death rates.”
Molnupiravir, a drug Merck thinks “may be the answer to Covid-19”, is now all the rage. The company will be asking for authorization to use it, presumably in an EUA since there are “no other treatments for ambulatory (non-hospital) persons.”
That’s bull****, of course, but bull**** is the norm; just ignore the elephants in the room — all of them — for which we have a crap-ton of safety data spanning decades.
This is a “new molecule.” I looked at it. Those who are calling it Merckmectin or Phizermectin (that is, an “on-patent” reformulation of an extremely safe and widely-distributed drug) are making a serious error, and that error may kill you.
An experimental antiviral pill developed by Merck & Co (MRK.N) could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, according to data that experts hailed as a potential breakthrough in how the virus is treated.
Merck, the company that makes Ivermectin, stands to make $7 billion in 2021 alone on this newly patented medicine.
Merck Statement on Ivermectin use During the COVID-19 Pandemic
Pfizer said Monday its research shows its product works for children aged five to 11 and that it will also seek U.S. authorization for this age group soon — a key step toward protecting schoolchildren from the novel coronavirus.
What this screenshot demonstrates is that Pfizer’s new twice-daily pill for Covid utilizes an unknown protease inhibitor, while including a snip from this study showing that Ivermectin also acts as a protease inhibitor.
Just another data point in favor of Ivermectin.
Pfizer is so confident the pill will be approved and likely mandated that it has started production before the end of clinical trials.
A mother from Ohio talks about her 12-year-old daughter who suffers from extreme reactions and almost died after volunteering for the Pfizer coronavirus vaccine trial.
h/t Marvin
Statements in this site are substantiated with facts that will stand in a court of law. Informed Consent requires a flow of information. Click on the hyperlinked sections to direct you to primary sources such as CDC, WHO, FDA documents.
Anyone trying to take down this site will be named as codefendant in Nuremberg 2.0 for being an accomplice to crimes against humanity. That includes social media. Lawyers are standing by.
Europeans will wait just one week for their Pfizer shipments to return to normal levels, while Canadians will wait for four weeks.
